Graticule Asia Macro Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Graticule Asia Macro Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-346,500	Closed	-$1.84M	–	143
2021 Q1	$1.84M	Sell	346,500 -134,784	-28%	-$772K	0.31%	89
2020 Q4	$2.59M	Buy	481,284 +297,804	+162%	+$1.62M	1.24%	28
2020 Q3	$1.46M	Buy	+183,480	New	+$1.61M	0.14%	57
2018 Q4	–	Sell	-185,000	Closed	-$2.51M	–	86
2018 Q3	$2.51M	Buy	185,000 +105,000	+131%	+$1.1M	0.14%	92
2018 Q2	$950K	Sell	80,000 -336,457	-81%	-$4.2M	0.06%	103
2018 Q1	$4.68M	Sell	416,457 -232,188	-36%	-$2.03M	0.5%	41
2017 Q4	$4.33M	Buy	648,645 +252,821	+64%	+$1.95M	0.8%	26
2017 Q3	$3.24M	Buy	+395,824	New	+$2.47M	0.15%	74
2016 Q1	–	Sell	-50,000	Closed	-$603K	–	83
2015 Q4	$603K	Buy	+50,000	New	+$490K	0.1%	154

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Graticule Asia Macro Advisors's ADAP Position: Q2 2021 in Review

Graticule Asia Macro Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2021, closing a stake of 346,500 shares — an estimated $1.84M sold.

Graticule Asia Macro Advisors first reported a position in ADAP in Q4 2015 and held it in 9 quarters. The position peaked at $4.68M in Q1 2018. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

Graticule Asia Macro Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2021 after selling out during the quarter.
Graticule Asia Macro Advisors sold 346,500 Adaptimmune Therapeutics shares in Q2 2021, an estimated $1.84M.
Graticule Asia Macro Advisors first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 9 quarters.
Graticule Asia Macro Advisors's Adaptimmune Therapeutics position peaked at $4.68M in Q1 2018.
82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.